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controlled trials of antibiotic treatment for acute
bacterial skin and skin structure infections in the
emergency department setting
Michael Quirke1 and Abel Wakai1,2*
Abstract
Acute bacterial skin and skin structure infections (ABSSSIs), which include cellulitis, abscesses, and wound infections,
are among the most commonly encountered conditions in emergency departments (EDs) internationally. Primarily,
as a result of the recent epidemic of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) in
North America, ED attendances and hospital admissions secondary to ABSSSIs have increased significantly. First-line
antibiotic drug therapies for ABSSSIs have therefore changed to take account of CA-MRSA and the threat of evolving
antibiotic resistance. Prior to 2010, randomized controlled trials (RCTs) of antibiotic therapy for ABSSSI used broad trial
inclusion criteria and utilized investigator-determined clinical resolution, 7 to 14 days after the end of therapy, as the
primary outcome measure. In order to produce more objective, reproducible, and quantifiable primary outcome
measures, the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research and a multidisciplinary
consortium convened by the Foundation for the National Institutes of Health (FNIH) issued significantly changed trial
guidance criteria. The currently recommended primary outcome measure is an assessment of greater than 20% reduction
in the area of erythema, edema, or induration from baseline, measured at 48 to 72 h after randomization and initiation of
drug treatment. In contrast, the European Medicines Agency (EMA) still recommends measurement of clinical resolution
at a later time period. We discuss the evolution of changes to trial guidance criteria issued by the FDA since 1998 and the
potential difficulties of implementing the recommended primary outcome measured at an earlier time point in RCTs of
outpatient antibiotic treatment performed in the ED setting.
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Introduction
Cellulitis, abscesses, and wound infections, most recently
renamed as acute bacterial skin and skin structure infec-
tions (ABSSSIs) [1], represent a heterogeneous group of
infections that are commonly encountered in clinical
practice. In the emergency department (ED) setting,
ABSSSIs account for between 1.5% and 3% of all atten-
dances and, in a point prevalence survey of 12 European
hospitals, were second only to respiratory tract infection
as the most common cause for inpatient antibiotic ther-
apy [2-5]. Despite this incidence data, there is a paucity
of randomized controlled trial (RCT)-based evidence
and recommendations to guide the management of
ABSSSIs in the ED setting [6].
In the USA, community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) is the most common
identifiable cause of purulent skin infections in EDs [7].
Data from the National Ambulatory Medical Care Survey
showed that visits by patients with skin infections in-
creased from 32.1 to 48.1 visits per 1,000 population be-
tween 1997 and 2005 [8]. Rather than substituting for
methicillin-sensitive S. aureus as a primary cause of
ABSSSI, the advent of CA-MRSA was associated with
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increased ED attendances [9] and hospital admissions [10]
secondary to ABSSSI. CA-MRSA has now evolved to be-
come a nosocomial pathogen with distinct genetic lineages
causing infection in different hospital settings internation-
ally [11,12]. CA-MRSA is not confined to North American
EDs; a recent study showed that 22% of all purulent skin
and soft tissue infections attending a Spanish ED in 2010
cultured CA-MRSA [13].
In addition to antibiotic stewardship and infection con-
trol policies, it follows that the identification of new drug
therapies for ABSSSI is clinically important [14]. Equally
important is the rationalization of existing antibiotic treat-
ments for ABSSSIs, which are known to be heterogeneous
[3,15], lack RCT-based evidence [6], and are associated
with overtreatment of milder infections [15]. Whether to
treat abscesses with concomitant antibiotics in addition to
incision and drainage is also contentious, as most RCTs to
date have been underpowered [16,17].
The need for more objective, reproducible, and reliable
outcome measurements in RCTs of antibiotic treatment
for ABSSSI prompted revision of clinical trial guidance cri-
teria issued by the US Food and Drug Administration
(FDA) [18]. Over the past several decades, the primary out-
come measure of choice in clinical trials of antibiotic treat-
ment for ABSSSI has been an investigator-determined
clinical response, measured at 7 to 21 days after antibiotic
treatment. Although this is clinically intuitive, it does not
take account of factors which may influence response at a
later time point such as host immune response and spon-
taneous lesion regression [19]. In addition, an objective
and more reliable standard of measurement of the pri-
mary outcome would help ensure that evidence of super-
iority of a given treatment applies to ongoing and future
trials of ABSSSI treatment (constancy assumption). Any
new outcome measures would also have to be clinically
relevant [18]. Patient-reported outcome measures or how
a patient ‘feels, functions and survives’ have to date been
significantly underreported in clinical trials of ABSSSI
antibiotic therapy.
This review describes recommendations relevant to
the ED setting, from regulatory authorities in the United
States (US) and Europe concerning the measurement of
treatment outcomes and inclusion criteria for RCTs of
antibiotic therapy for ABSSSIs. Not only have there been
changes to disease nomenclature, but also a complete re-
vision of clinical trial entry criteria and the timing and
method of measurement of the primary outcome.
ABSSSI nomenclature
Nomenclature for this group of infections is confusing for
two major reasons. Firstly, phenomenological descriptions
of different types of infection (cellulitis, erysipelas, abscess),
predisposing conditions (diabetic foot ulcer), eponymous
diseases (Fournier’s gangrene, clostridial myonecrosis), and
microbiological causes of infection [20,21] have resulted in
heterogeneous terminology, much of which has only his-
torical relevance. Secondly, repeated classifications by the
US Food and Drug Administration (FDA) [1,22,23] and
the Infectious Diseases Society of America (IDSA) [24,25],
have resulted in inconsistencies in nomenclature. The term
ABSSSI reflects the most current definition of the disease
issued by the FDA for the purposes of performing and ap-
praising RCTs [1].
Previous FDA guidance
US regulations concerning the conduct of RCTs of anti-
biotic therapy for ABSSSI are issued in the form of
‘Guidance for Industry’ documents by the FDA Center
for Drug Evaluation and Research (CDER). In the 1998
guidance document, infections were classified as compli-
cated or uncomplicated [22] (Table 1).
Definitions for the inclusion of patients with infections
were broad, leaving much to the discretion of clinical
trial investigators. For example, there was no guidance
for the measurement of minimum lesion size. Patients
with a ‘major abscess’ were defined as having a ‘compli-
cated’ infection but with no other discriminatory fea-
tures; trial investigators undoubtedly enrolled a wide
variety of major and ‘minor’ infections [26]. There were
no clear restrictions to the number of patients enrolled
with abscess, which became problematic in the context
of the CA-MRSA epidemic in the US, with more pa-
tients enrolled from EDs with purulent skin and soft tis-
sue infections (SSTIs) [26,27]. The primary outcome
measure was ‘clinical cure’, interpreted as the resolution
of signs and symptoms based on physician’s observation,
need for alternative therapy, and patient comments [18].
Although intuitive, and still the primary outcome meas-
ure of choice in Europe, more objective, measurable, and
reproducible outcome measures were required [28].
In 2010, the FDA published new draft guidance [23].
Two major changes to both the timing and assessment
of the primary outcome were recommended. Firstly, the
FDA guidance recommended changing the timing of pri-
mary outcome measurement from 7 to 21 days after the
end of antibiotic treatment to an earlier measurement
within 48 to 72 h of treatment commencement. Secondly,
the new primary outcome recommended measuring ces-
sation of the spread of lesion erythema, edema, or indur-
ation, in addition to resolution of fever, whereas previous
guidance recommended investigator-determined clinical
response or ‘cure’. In arriving at this new primary outcome
measure, the FDA was guided by historical evidence from
two trials of antimicrobial therapy for ABSSSI. In 1937,
Snodgrass and Anderson performed two controlled trials
comparing sulphanilamide and prontosil (a pro-drug of
sulphanilamide) with antitoxin and UV light [29,30]. After
48 to 72 h of treatment, they recorded significant
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cessation in lesion spread and normalization of body
temperature in the group receiving antibiotic treatment.
Given that these two trials demonstrated historical evi-
dence of sensitivity to drug effects (HESDE), the FDA rec-
ommended this new early primary outcome measure and
as a secondary outcome, sustained clinical response at the
later test-of-cure visit.
However, numerous authors have questioned the val-
idity of using non-verifiable data obtained almost eight
decades ago [26,31,32]. Over half of patients receiving
sulphanilamide and 39% receiving ultraviolet (UV) light
improved on day zero making the timing of treatment
effect questionable. Furthermore, the constancy assump-
tion (that superiority shown in historical trials still ap-
plies today) may not apply due to advances in medical
care in the intervening years [28].
There was considerable controversy regarding the
utilization of cessation of lesion spread as the primary
outcome measure. Perhaps most significantly, cessation
of lesion spread indicates that the patient is on a path to
recovery rather than representing treatment success
[26,31]. However, measurement of clinical response at
an earlier time point is clinically intuitive. It is also more
likely to represent an actual treatment effect, as asses-
sing cure at a later time point introduces the confound-
ing influences of host immune response and natural
regression of the infection [19]. Evidence from recent
trials supports early measurement of clinical response.
In the ESTABLISH-2 study, the majority (>80%) of cases
of ABSSSI showed early clinical response, which was
sustained at the later assessment (0.7% to 3.8% of initial
responders were deemed to have an ongoing infection at
the later test-of-cure assessment) [33].
Given these controversies, the FDA commissioned a
multidisciplinary report from the Foundation for the Na-
tional Institutes of Health (FNIH) Biomarkers Consor-
tium. This consortium analyzed both historical data and
data from recently published trials which examined this
new efficacy endpoint in conjunction with the older end-
point of ‘clinical cure’.
Current FDA guidance
Definitions of ABSSSI
ABSSSIs are defined as cellulitis or erysipelas, wound in-
fections, and abscesses of at least 75 cm2 measured by
the area of redness, edema, or induration [1]. Measure-
ment of the area of erythema has shown high inter-
observer reliability when using a plastic ruler [34], but
other methods such as planimetry and digital photography
are poorly tested [18]. It is still unclear whether lesion
diameter dictates infection severity [26]. In addition, there
are currently no recommendations for measuring lesion
size in pediatric patients, small adults, or specific body
parts such as the face, hand, and perineum.
Clinical trial design, populations, and entry criteria
A mixture of the different ABSSSI disease entities should
be included with a cap of 30% on the number of major
abscesses enrolled [1]. The 2013 guidance does not specify
that elevated body temperature is a requirement for enroll-
ment. This contrasts with 2010 guidance which required
four-hourly measurement of patient body temperature
[23]. Two recent trials have shown that only 18 to 34% of
patients with complicated ABSSSI have fever at baseline
[35,36]. Requirement for elevated body temperature at
enrollment could potentially exclude elderly patients,
Table 1 Summary of relevant nomenclature issued by the US FDA and the Infectious Diseases Society of America
(IDSA)
Source Descriptor Clinical conditions included
FDA 1998 [22] Uncomplicated skin and skin
structure infection
Abscess, cellulitis, impetigo, furuncle
Complicated skin and skin structure
and soft tissue infection
Infections of deeper soft tissue or requiring significant surgical intervention (infected ulcers,
burns, major abscess), or a significant underlying disease state that complicates response to
treatment
FDA 2010 [23]
and 2013 [1]
Acute bacterial skin and skin
structure infections (ABSSSIs)
Bacterial infection of the skin with a minimum size of >75 cm2. Includes:
•Cellulitis/erysipelas
•Wound infection
•Major cutaneous abscess
IDSA 2011 [24] Purulent cellulitis Cellulitis associated with purulent drainage or exudate in the absence of a drainable
abscess
Non-purulent cellulitis Cellulitis with no purulent drainage or exudate and no associated abscess
IDSA 2014 [25] Purulent skin and soft tissue
infection (SSTI)
Abscess, furuncle, carbuncle, inflamed epidermoid cyst
Non-purulent SSTI Cellulitis, erysipelas, necrotizing fasciitis
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diabetics, and the immunocompromised, leading some
authors to question whether fever is even on the causal
pathway of the disease [18].
Limiting the number of patients with abscess to less
than 30% of trial participants will minimize the bias that
surgical treatment of abscesses may introduce to the
RCT, and prevent overrepresentation of abscesses from
regions where purulent cellulitis is more commonly en-
countered [1]. The role of adjunctive antibiotic therapy
for abscess is contentious; since the majority of abscesses
can be cured with incision and drainage alone [37,38],
and many previous trials included smaller abscesses [31],
very large sample sizes are required to show small differ-
ences in response rates [39].
Prior antibacterial drug therapy
Patients should ideally not have received any antibiotic
therapy prior to trial enrollment unless there is objective
evidence of the ABSSSI deteriorating while on treatment
[1]. However, excluding all patients who previously re-
ceived treatment would result in a population with a less
severe illness (bias towards non-inferiority) and limit the
external validity of the trial results. To address this, the
FDA suggests ‘pragmatic’ approaches including prompt
enrollment procedures and allowing less than 25% of the
total population enrolled to have received a single dose of a
short-acting antibiotic [1]. However, in the clinical setting,
delaying the first dose of antibiotic to a patient while await-
ing trial enrollment and randomization may not represent
an acceptable standard of care and may be unethical. Since
many patients attending EDs have already commenced oral
antibiotic treatment, particularly in areas with developed
primary care services, it will also be challenging to docu-
ment objective clinical progression when the patient is be-
ing treated by a different practitioner.
Measurement of primary outcome measure
The primary outcome measure should assess for 20% or
greater reduction in lesion size when measured at 48 to
72 h compared to baseline [1]. The timing and nature of
this outcome measure is supported by evidence from re-
cent RCTs [33,36,40], which demonstrate the feasibility
of measurement at this time point. Further advantages
of early assessment of the primary outcome include early
identification of treatment failure, earlier de-escalation
of broad-spectrum antibiotics, and possibly, earlier dis-
charge on oral therapy [41].
Measurement of secondary outcome measures
According to the most recent FDA guidance, the second-
ary outcome measure should be investigator-determined
clinical resolution measured between 7 and 14 days after
the completion of therapy [1]. Measurement of clinical
resolution at a specified time point after the end of
treatment is important to provide evidence of a sustained
effect and longer-term patient-reported outcome mea-
sures (PROMs) [18].
Measurement of reduction in the area of erythema
represents a more objective, quantifiable, and reproducible
primary outcome assessment than clinical cure at the end
of therapy. However, there is still controversy regarding
what constitutes a clinically meaningful trial outcome
measure for RCTs of ABSSSI treatment [18,19,31]. A re-
duction in the area of erythema may not have any mean-
ingful impact on how a patient functions or feels [18].
Previous FDA guidance was criticized for measuring ces-
sation in lesion spread as the primary outcome measure,
which may not, in reality, translate to a clinically success-
ful treatment for patient or assessing physician [31]. As-
sessment of PROMs in RCTs of drug therapy for ABSSSI
is overall lacking and deserving of further study.
It is worth noting that although the FDA issues guide-
lines pertaining to clinical trial design, the guidelines are
not binding but represent ‘current thinking’ on issues re-
lated to trial design (Table 2). Several recent trials of
ABSSSI antibiotic treatment have incorporated recom-
mended outcome measures [33,36,42,43], including more
recently PROMs [33].
European Medicines Agency (EMA) guidance
The primary outcome measure recommended by the
EMA is an investigator-determined clinical outcome
(cure, failure, or indeterminate responses) measured at 7
to 14 days after the end of therapy. The EMA primary
outcome measure is the same as the FDA-recommended
secondary outcome measure [1]. Provided sponsors cap-
ture both early and late outcomes in multinational trials,
separate analyses for US and European authorities are
possible, and the same study could satisfy both sets of
requirements [18]. It is likely that the development of
two separate clinical development programs will incur
significant costs to trial sponsors [31].
ED outcome measures for RCTs of antibiotic treatment for
ABSSSIs
The feasibility of employing the recent FDA-recommended
primary efficacy outcome measure (reduction in lesion size
48 to 72 h after randomization to treatment) may be chal-
lenging in ED-based RCTs of antibiotic treatment for
ABSSSIs. ED-specific challenges to patient recruitment
such as overcrowding and loss to follow-up of recruited
patients who may not live in the ED’s catchment region are
well recognized [44]. In an ED-based RCT for uncompli-
cated ABSSIs in children, in which trial participants were
assessed by either a review visit or a phone call between 2
and 3 days post-enrollment, 35% to 38% of patients were
followed up by a phone call [45]. This indicates potential
difficulties in achieving objective measurement of the
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current FDA-recommended primary outcome measure in
the ED setting [1].
Other trials of outpatient antibiotic therapy for ABSSSIs
performed in the ED-setting have used investigator-
determined clinical resolution of disease at the test-of-
cure visit [9,46-49]. Although this latter primary outcome
measure is less challenging to use in the ED setting, it can
now be considered to have been superseded by the more
recent FDA-recommended primary outcome measure (re-
duction in lesion size 48 to 72 h after randomization to
treatment). Aside from requiring a considerably greater fi-
nancial investment in terms of achieving day 3 follow-up,
innovative measures of patient follow-up should be con-
sidered in future ED-based RCTs of outpatient antibiotic
treatment for ABSSSIs to overcome some of the current
challenges. For example, future ED-based RCTs could
examine the feasibility of using telemedicine (including
handheld devices such as mobile phones or tablet com-
puters) or web-based platforms for trial participant
follow-up.
Conclusions
In the context of the recently updated 2013 FDA guid-
ance regarding the conduct of RCTs of antibiotic treat-
ment for ABSSSIs, it is timely for emergency medicine
professional organizations, such as the Society for
Academic Emergency Medicine (SAEM) in the US and
the European Society for Emergency Medicine (EuSEM),
to develop consensus recommendations to guide emer-
gency medicine researchers on which outcome measures
to use for ED-based RCTs of antibiotic therapy for
ABSSSIs. In the meantime, emergency medicine re-
searchers should use the primary outcome measure of
reduction in lesion size between 2 and 3 days after
randomization and clinical cure 7 to 14 days post end of
therapy for ED-based RCTs of antibiotic treatment for
ABSSSIs.
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Table 2 Summary of FDA guidance document issued in 2013 and potential issues in implementation
FDA guidance 2013 Potential issues
Definitions of ABSSSI
Cellulitis or erysipelas, wound infections, and abscesses with at least
75 cm2 area of redness, edema, or induration.
Lesion size >75 cm2 is arbitrary [26].
Minimum lesion size of 75 cm2 differentiates ‘minor’ cutaneous abscess
from ‘major’ abscess.
Minimum lesion size may exclude key groups (pediatric, small adults)
and body parts (face, hand, genitalia) [28].
Measurement of induration and edema is subjective [28].
Depth of involvement may be more important than diameter [26].
Clinical trial design, populations, and entry criteria
Mixture of ABSSSI entities. Conflicting evidence regarding the efficacy of drug therapy for ‘minor’
abscess.
Limit on number of major abscesses to ≤30% of total enrolled.
No requirement for elevated body temperature at enrollment. Abscess less common in European ED settings than in North America
due to lower prevalence of CA-MRSA.
Prior antibacterial drug therapy
Encourage prompt enrollment procedures. Prompt enrollment is difficult to achieve in many ED settings.
Allow enrollment of small number of patients who have received a single
dose of a short-acting antibacterial drug within the previous 24 h.
Many ED patients have commenced therapy on presentation in areas
with developed primary care services.
Allow enrollment of patients with objective documentation of clinical
progression while on antibacterial therapy (i.e. not based on history alone).
Difficult to obtain objective evidence of clinical progression of previously
treated ABSSSI, where treatment commenced in primary care.
Outcome measures and timing of assessments
Primary outcome measure of lesion response at 48 to 72 h (≥20%
reduction in lesion size when measured compared to baseline).
Achieving reliable endpoint measurement in trials of outpatient oral
therapy may be difficult in ED setting, with higher loss to follow-up rate.
Secondary efficacy endpoint is a resolution of ABSSSI 7 to 14 days after
completion of therapy.
No evidence that reduction in the size of lesion represents how patients
feel or function [28].
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